Atrial fibrillation (AFib) increases the risk of stroke. Several tools assist in estimating this risk and informing treatment decisions. These tools consider various factors, such as age, sex, presence of heart failure, hypertension, diabetes, prior stroke or transient ischemic attack (TIA), and vascular disease. By inputting patient-specific data, a risk score is generated, reflecting the likelihood of stroke within a specified timeframe.
The determination of stroke risk in individuals with AFib is essential for guiding the selection of appropriate anticoagulation therapy. Accurate risk stratification allows clinicians to weigh the benefits of stroke prevention against the potential risks of bleeding associated with anticoagulants. Historically, clinicians relied on less formalized assessment methods, leading to inconsistencies in treatment. Standardized evaluation methods contribute to more consistent and evidence-based management of patients with AFib, improving overall outcomes.
